Ascendis Pharma's TransCon CNP Shows Durable Growth Benefits in Achondroplasia Trial
Event summary
- Two-year data from Ascendis Pharma's ApproaCH trial showed sustained improvements in growth and body proportionality for children with achondroplasia treated with TransCon CNP (navepegritide).
- The trial, involving 84 children aged 2–11, demonstrated continued benefits through Week 104, with strong retention and no severe adverse events.
- TransCon CNP, approved as YUVIWEL® by the FDA in February 2026, is under review by the European Medicines Agency with a decision expected in Q4 2026.
The big picture
Ascendis Pharma's positive two-year data for TransCon CNP reinforces its potential as a transformative treatment for achondroplasia, a rare genetic condition affecting over 250,000 people worldwide. The durable benefits observed in the ApproaCH trial position the company favorably in the growing rare disease therapeutics market, particularly as it seeks regulatory approval in key markets. The strategic focus on once-weekly administration and continuous exposure of active CNP could set a new standard for treating conditions driven by overactive FGFR3 signaling.
What we're watching
- Regulatory Approval
- Whether the European Medicines Agency will approve TransCon CNP by the anticipated Q4 2026 deadline, following its FDA approval.
- Market Adoption
- The pace at which TransCon CNP gains market acceptance and reimbursement coverage for achondroplasia treatment.
- Long-term Efficacy
- How sustained the benefits of TransCon CNP will be over extended treatment periods, as indicated by ongoing and future trials.